4.5 Article

Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer

Related references

Note: Only part of the references are listed.
Article Oncology

Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer

Kent F. Hoskins et al.

Summary: Black women with hormone receptor-positive breast cancer have a significant survival disparity compared to other subtypes. This study examined the contributions of social determinants of health and tumor biology to this disparity and found that 44% of the racial difference can be explained by these factors.

JAMA ONCOLOGY (2023)

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Article Surgery

Inflammatory breast cancer, trimodal treatment, and mortality: Does where you live matter?

Theresa Relation et al.

Summary: The study found that disease-specific mortality among inflammatory breast cancer patients is primarily associated with tumor biology and patient characteristics rather than treatment disparities or neighborhood socioeconomic status.

SURGERY (2022)

Article Oncology

Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer

Laura E. G. Warren et al.

Summary: This study retrospectively analyzed the occurrence of central nervous system metastasis (mCNS) in patients with inflammatory breast cancer (IBC) between 1997 and 2019 and identified several risk factors. The research found that triple-negative tumor subtype, visceral metastasis as the first site, and younger age at diagnosis of metastatic disease were significant risk factors for mCNS.

CANCER (2022)

Article Oncology

Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database

Hannah Grace Abraham et al.

Summary: This study analyzed the incidence and survival of inflammatory breast cancer (IBC) in the US over four decades. The overall IBC incidence was 2.76 cases per 100,000 people, with white patients at 2.63, black patients at 4.52, and patients of other races at 1.84. Despite improved survival rates, a persistent disparity remains between white and black patients over two decades.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Article Oncology

Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis

Dechuang Jiao et al.

Summary: Previous studies have shown lower survival rates in inflammatory breast cancer (IBC) patients compared to non-inflammatory local advanced breast cancer (non-IBC) patients. However, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients had not been explored. In this study, it was found that patients with IBC and T4-non-IBC had similar breast cancer-specific survival (BCSS) rates in the modern systemic treatment era. Furthermore, it was observed that in IBC patients, the HR-/HER2+ subtype had a better outcome, while the HR-/HER2- subtype had a poorer outcome compared to T4-non-IBC patients.

BMC CANCER (2021)

Article Oncology

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Larissa A. Korde et al.

Summary: The guideline recommendations for neoadjuvant therapy for breast cancer suggest that patients should be managed by multidisciplinary teams and that appropriate candidates include those with inflammatory breast cancer or residual disease that may prompt a change in therapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Surgery

Inflammatory Breast Cancer What to Know About This Unique, Aggressive Breast Cancer

Arjun Menta et al.

SURGICAL CLINICS OF NORTH AMERICA (2018)

Review Oncology

Inflammatory breast cancer biology: the tumour microenvironment is key

Bora Lim et al.

NATURE REVIEWS CANCER (2018)

Review Mathematical & Computational Biology

Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement

Peter C. Austin et al.

STATISTICS IN MEDICINE (2017)

Article Oncology

Epidemiological risk factors associated with inflammatory breast cancer subtypes

Rachel L. Atkinson et al.

CANCER CAUSES & CONTROL (2016)

Review Oncology

Inflammatory breast cancer: An overview

D. J. P. van Uden et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)

Article Oncology

Risk Factors for Inflammatory Breast Cancer and Other Invasive Breast Cancers

Catherine Schairer et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)

Article Biochemistry & Molecular Biology

Mutational Processes Molding the Genomes of 21 Breast Cancers

Serena Nik-Zainal et al.

Article Multidisciplinary Sciences

The landscape of cancer genes and mutational processes in breast cancer

Philip J. Stephens et al.

NATURE (2012)

Article Multidisciplinary Sciences

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

Sohrab P. Shah et al.

NATURE (2012)

Article Oncology

What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

Dora Il'yasova et al.

BREAST CANCER RESEARCH AND TREATMENT (2011)

Article Oncology

Inflammatory Breast Cancer The Disease, the Biology, the Treatment

Fredika M. Robertson et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2010)

Article Oncology

Inflammatory breast carcinoma:: Pathological or clinical entity?

RS Amparo et al.

BREAST CANCER RESEARCH AND TREATMENT (2000)